Trial Profile
Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Registrational; Therapeutic Use
- Acronyms MILES
- Sponsors Pfizer
- 11 Oct 2023 Safety end-point is removed, thus removing "AR" from trial focus.
- 11 Oct 2023 Safety end-point is removed, thus removing "AR" from trial focus.
- 11 Oct 2023 Safety end-point is removed, thus removing "AR" from trial focus.